Skip to main content

Table 3 Specialist services and pharmaceuticals for the entire cohort

From: Two-year follow-up of a clustered randomised controlled trial of a multicomponent general practice intervention for people at risk of poor health outcomes

 

Control

Intervention

Intervention effecta

Baseline

12 months

24 months

Baseline

12 months

24 months

IRR (95% CI)

P-value

No. patients in the analysis

501

501

501

514

514

514

  

Specialist services

18,205

17,729

16,336

18,904

18,349

17,179

0.99 (0.89 to 1.09)b

0.78

 Mean (SD)

36.34 (37.23)

35.39 (49.04)

32.61 (35.82)

36.78 (31.79)

35.70 (35.59)

33.42 (41.44)

0.99 (0.91 to 1.09)c

0.90

Pharmaceuticals

26,790

26,780

26,613

27,449

27,294

27,124

1.00 (0.94 to 1.06)b

0.78

 Mean (SD)

53.47 (37.44)

53.45 37.32

53.12 39.71

53.40 37.24

53.10 36.93

52.77 38.20

1.00 (0.95 to 1.04)c

0.94

  1. Data are the number and mean (standard deviation [SD]) per patient of specialist services and pharmaceutical items supplied
  2. aThe intervention effect (incidence rate ratio [IRR]) is calculated from a multilevel negative binomial regression model for the difference between the control and intervention groups over bone or ctwo years. The dataset comprises 1015 (97.2%) of 1044 patients who were matched to Services Australia records. Baseline, the 12-month period prior to the intervention; 12 months, the 12-month intervention period; 24 months, the 12-month period following the intervention period; CI, confidence interval
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us